August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights - Prostate Cancer
Chicago, IL—The results from 2 studies should advance the use of abiraterone acetate (Zytiga) to the frontline treatment of patients with hormone-sensitive advanced prostate cancer, effectively replacing chemotherapy, said several experts at the 2017 ASCO annual meeting.
￼A Multidisciplinary Approach to the Treatment of Prostate Cancer: Providing Therapies That Improve Overall Survival and Quality of Life
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology - In the Literature, Prostate Cancer
- Ixazomib Extends Progression-Free Survival in Multiple Myeloma
- Pembrolizumab Shows Potential Antitumor Activity in Advanced Gastric Cancer
- ASCO Endorses Canadian Clinical Practice Guideline on Active Surveillance for Localized Prostate Cancer
- Delayed Relapses After Anti–PD-1 Therapy Linked to Mutation in Patients with Melanoma
Is the Glass Half Empty or Half Full? First Study Compares Robotic-Assisted Surgery and Open Radical Prostatectomy
The first randomized trial to compare robotic-assisted prostatectomy with conventional open radical prostatectomy found no meaningful differences between these techniques in urinary and sexual function or in the rate of positive surgical margins in men with localized prostate cancer in the first 12 weeks after surgery (Yaxley JW, et al. Lancet. 2016 Jul 26. Epub ahead of print). The 24-month results will be published at a later time.
Men with intermediate-risk prostate cancer can safely undergo radiation administered in larger fractions for 4 weeks (moderate hypofractionation) as an alternative to conventional radiation administered for 8 weeks, according to the results of a randomized, controlled, noninferiority clinical trial presented at ASCO 2016.
The upfront addition of docetaxel to androgen deprivation therapy (ADT) adds more than 1 year to overall survival compared with ADT alone in men with newly diagnosed hormone-sensitive prostate cancer, according to findings from a phase 3 study funded by the National Cancer Institute.
Chicago, IL—A lack of awareness of active surveillance prevents more men with early-stage prostate cancer from choosing this option, according to a study funded by the Centers for Disease Control and Prevention (CDC), which showed that African-American men are more influenced by convenience than Caucasian men in their choice of treatment. Spouses and significant others are also influential in the decision, and they tend to be less enthusiastic about active surveillance than the men who have prostate cancer.
New Analysis Confirms Radium Ra-223 Prolongs Survival in Patients with Metastatic CRPC, Regardless of Previous Docetaxel Therapy Status
Chicago, IL—Results of a new subgroup analysis of the ALSYMPCA study that were presented at ASCO 2013 showed that radium Ra-223 dichloride (Xofigo) significantly prolongs overall survival (OS) and has a highly favorable safety profile in patients with metastatic castration-resistant prostate cancer (CRPC), regardless of whether they had previously received docetaxel therapy.
Exploring Men’s Willingness to Pay for Prostate Cancer Screening to Avoid Unnecessary Biopsy and Treatment
Dutch researchers have peered into the minds and wallets of a group of men aged 55 to 75 years to determine what they are willing to trade for a reduced risk of prostate cancer–related death or to avoid unnecessary procedures and treatment.
Chicago, IL—The novel androgen receptor–signaling inhibitor enzalutamide, also known as MDV3100, significantly prolonged overall survival (OS), slowed disease progression, and improved quality-of-life (QOL) measures in men with castration-resistant prostate cancer after docetaxel failure, according to results from a large phase 3 clinical trial.
Page 1 of 2
Results 1 - 10 of 17
Results 1 - 10 of 17